Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services.
Takayama S, Kinoshita T, Shiino S, Jimbo K, Watanabe KI, Fujisawa T, Yamamoto N, Onishi T, Shien T, Ito M, Takahashi M, Futamura M, Aruga T, Kaneko K, Suto A. Takayama S, et al. Among authors: aruga t. JMA J. 2023 Oct 16;6(4):505-512. doi: 10.31662/jmaj.2023-0047. Epub 2023 Oct 2. JMA J. 2023. PMID: 37941717 Free PMC article. Clinical Trial.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: aruga t. Int J Clin Oncol. 2021 Jul;26(7):1229-1236. doi: 10.1007/s10147-021-01920-0. Epub 2021 Apr 23. Int J Clin Oncol. 2021. PMID: 33891194 Free PMC article. Clinical Trial.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: aruga t. Int J Clin Oncol. 2021 Jul;26(7):1237. doi: 10.1007/s10147-021-01940-w. Int J Clin Oncol. 2021. PMID: 34043103 Free PMC article. No abstract available.
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).
Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Tokunaga E, et al. Among authors: aruga t. Cancers (Basel). 2021 Aug 9;13(16):4008. doi: 10.3390/cancers13164008. Cancers (Basel). 2021. PMID: 34439165 Free PMC article.
Evaluation of a novel medical device for pegfilgrastim administration.
Aruga T, Doihara H, Yanagita Y, Ishida T, Yamashita T, Uehara K, Taira T, Tsurutani J, Takeshita T, Tsuyuki S, Kaneko K, Ohtake T, Yamaguchi Y, Hara Y, Saji S. Aruga T, et al. Cancer Sci. 2022 May;113(5):1763-1770. doi: 10.1111/cas.15335. Epub 2022 Mar 29. Cancer Sci. 2022. PMID: 35293085 Free PMC article.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: aruga t. Int J Clin Oncol. 2022 Nov;27(11):1793. doi: 10.1007/s10147-022-02237-2. Int J Clin Oncol. 2022. PMID: 36166110 Free PMC article. No abstract available.
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H, Nakamura R, Masuda N, Yamashita T, Yamamoto Y, Kobayashi K, Tsurutani J, Iwasa T, Yonemori K, Tamura K, Aruga T, Tokunaga E, Kaneko K, Lee MJ, Yuno A, Kawabata A, Seike T, Kaneda A, Nishimura Y, Trepel JB, Saji S. Iwata H, et al. Among authors: aruga t. Jpn J Clin Oncol. 2023 Jan 6;53(1):4-15. doi: 10.1093/jjco/hyac166. Jpn J Clin Oncol. 2023. PMID: 36398439 Free PMC article. Clinical Trial.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, Yasojima H, Bando H, Nakamura R, Yamanaka T, Ishida K, Aruga T, Yanagita Y, Tokunaga E, Aogi K, Ohno S, Kasai H, Kataoka TR, Morita S, Toi M. Takano T, et al. Among authors: aruga t. Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333-7. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38767786
257 results